ClinicalTrials.gg
RecruitingNCT06450925Updated Aug 24, 2026

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

A Phase 2 interventional study of Vitamin A and Placebo in Graft Vs Host Disease, Vitamin A Deficiency and Vitamin D Deficiency, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.

Read the detailed description

Hematopoietic stem cell transplantation (HSCT) is an effective treatment strategy for many malignancies, marrow failure syndromes, and immune deficiencies in children, adolescents, and adults. Vitamin A and its derivatives regulate growth and differentiation of intestinal cells, and vitamin A deficiency is associated with increased susceptibility to infection in both human and animal models. The investigators' preliminary data suggest lower vitamin A levels were associated with an increased incidence of gastrointestinal graft versus host disease (GI GVHD) in patients undergoing HSCT.

This study is a randomized double blinded comparison of vitamin A supplementation comparing a single large dose of vitamin A with a placebo.

02

Conditions studied

  • Graft Vs Host Disease
  • Vitamin A Deficiency
  • Vitamin D Deficiency
03

In context

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

This study's planned enrollment of 190 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.

Browse Graft vs Host Disease studies →

Lead sponsor

Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 130 are open to participants now.

Of its 57 completed or terminated interventional studies of FDA-regulated products, 31 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18 years of age or older
  • Be scheduled for stem cell transplant.
  • Have a vitamin A level \< for age.
  • Be able to tolerate enteral vitamin dose administration.
  • Have a total level \< 1.5x ULN and an and/or ALT\< 3xULN for age
  • Receiving PBSCs as stem cell graft

Exclusion criteria

Exclusion Criteria:

  • Ongoing raised intracranial pressure (see appendix D for definition of raised intracranial pressure)
  • Liver cirrhosis (see appendix C for definition of liver cirrhosis)
  • Patients will be excluded if they are currently pregnant.
  • Patients will be excluded if they have a fish (not shellfish) allergy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • Active comparator
    Vitamin A

    Route of administration: Oral. Frequency: Once. Timing: Pre-transplant Dose of Vit A: 1.2 mg/kg, max dose 75 mg Formulation of Vit A: 2.5 mg liquid filled oral capsules. Vitamin A level assessment: Vitamin A levels will be measured pre-transplant and again at day +30 (± 10 days)

    Drug: Vitamin A

  • Placebo comparator
    Placebo

    Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.

    Other: Placebo

Interventions

  • Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.

  • OtherPlacebo

    Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.

06

What researchers measure

Primary outcomes

  1. Incidence of moderate-severe chronic graft versus host disease (GVHD)

    Incidence of moderate-severe chronic GVHD

    Time frame: 1 year after transplant

Secondary outcomes

  1. Incidence of acute gastrointestinal graft versus host disease (GI GVHD)

    Incidence of acute GI GVHD

    Time frame: 2 years after transplant

  2. Incidence of relapse

    Incidence of relapse

    Time frame: 2 years after transplant

  3. Overall survival.

    Overall survival.

    Time frame: 2 years after transplant

07

Study locations

3 of 3 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06450925
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Mar 25, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2029 (estimated)
Last update
Aug 24, 2026

Study contacts

Celeste Dourson, MS, CCRP
Contact
celeste.dourson@cchmc.org
513-636-7679
Pooja Khandelwal, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin A

Start the discussion